StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

Earnings

UroGen Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 1, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$89.00M
+223.6% on a year earlier
EPS, Q3 FY2026
-$0.03
-$0.69 a year earlier
Latest guidance
Lowered
Nov 4, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of UroGen Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 1, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026before the open$89.00M+223.6%-$0.03Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$51.00M––Release
Q4 FY2025ended Dec 31, 2025Mar 2, 2026before the open$37.84M+53.8%-$0.54Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$27.50M+9.1%-$0.69Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$24.20M+11.0%-$1.05Release
Q1 FY2025ended Mar 31, 2025May 12, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 10, 2025before the open$24.60M+4.7%-$0.80Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024before the open$25.20M+20.6%-$0.55Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024before the open$21.80M+3.3%-$0.91Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open$18.80M+9.3%-$0.97Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

UroGen Pharma's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
net product revenue for JELMYTOFY2026$97.00M – $101.00M$97.00M – $101.00MReaffirmedAug 5, 2026
net product revenue guidance for JELMYTOFY2026$90.00M–NewNov 4, 2026
year-over-year growth rateFY2026+3% – +7%+3% – +7%ReaffirmedAug 5, 2026
non-cash share-based compensation expenseFY2026$20.00M – $24.00M–LoweredNov 4, 2026
non-cash share-based compensation expenseFY2026$20.00M – $24.00M$20.00M – $24.00MLoweredAug 5, 2026
operating expensesFY2026$260.00M – $270.00M–NewNov 4, 2026
operating expensesFY2026$260.00M – $270.00M$240.00M – $250.00MRaisedAug 5, 2026

Guidance history

Every forecast UroGen Pharma put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026operating expensesFY2026$260.00M – $270.00MNew
Nov 4, 2026non-cash share-based compensation expenseFY2026$20.00M – $24.00MLowered
Nov 4, 2026net product revenue guidance for JELMYTOFY2026$90.00MNew
Aug 5, 2026operating expensesFY2026$260.00M – $270.00MRaised
Aug 5, 2026non-cash share-based compensation expenseFY2026$20.00M – $24.00MLowered
Aug 5, 2026year-over-year growth rateFY2026+3% – +7%Reaffirmed
Aug 5, 2026net product revenue for JELMYTOFY2026$97.00M – $101.00MReaffirmed
May 6, 2026operating expensesFY2026$240.00M – $250.00MRaised
May 6, 2026non-cash share-based compensation expenseFY2026$20.00M – $24.00MLowered
May 6, 2026year-over-year growth rateFY2026+3% – +7%Reaffirmed
May 6, 2026net product revenue for JELMYTOFY2026$97.00M – $101.00MReaffirmed
Mar 2, 2026operating expensesFY2026$240.00M – $250.00MNew
Mar 2, 2026non-cash share-based compensation expenseFY2026$20.00M – $24.00MLowered
Mar 2, 2026year-over-year growth rateFY2026+3% – +7%New
Mar 2, 2026net product sales for JELMYTOFY2026$97.00M – $101.00MNew
Nov 6, 2025operating expensesFY2025$215.00M – $225.00MNew
Nov 6, 2025non-cash share-based compensation expenseFY2025$11.00M – $14.00MLowered
Nov 6, 2025year-over-year growth rateFY2025+8% – +12%New
Nov 6, 2025net product revenues for JELMYTOFY2025$94.00M – $98.00MNew
Aug 7, 2025operating expensesFY2025$215.00M – $225.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases UroGen Pharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Results
  12. News
  13. News
  14. Update
  15. Results

See a number that looks wrong?